- Home
- LXP vs CPRX Comparison
LXP vs CPRX Comparison
Compare LXP & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXP
- CPRX
- Stock Information
- Founded
- LXP 1993
- CPRX 2002
- Country
- LXP United States
- CPRX United States
- Employees
- LXP N/A
- CPRX N/A
- Industry
- LXP Real Estate Investment Trusts
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- LXP Real Estate
- CPRX Health Care
- Exchange
- LXP Nasdaq
- CPRX Nasdaq
- Market Cap
- LXP 2.5B
- CPRX 2.6B
- IPO Year
- LXP 1993
- CPRX 2006
- Fundamental
- Price
- LXP $8.24
- CPRX $20.07
- Analyst Decision
- LXP Hold
- CPRX Strong Buy
- Analyst Count
- LXP 3
- CPRX 5
- Target Price
- LXP $10.50
- CPRX $33.20
- AVG Volume (30 Days)
- LXP 3.7M
- CPRX 1.4M
- Earning Date
- LXP 07-30-2025
- CPRX 08-06-2025
- Dividend Yield
- LXP 6.56%
- CPRX N/A
- EPS Growth
- LXP 203.57
- CPRX 183.96
- EPS
- LXP 0.27
- CPRX 1.65
- Revenue
- LXP $363,003,000.00
- CPRX $558,499,000.00
- Revenue This Year
- LXP N/A
- CPRX $16.37
- Revenue Next Year
- LXP $6.85
- CPRX $8.80
- P/E Ratio
- LXP $30.48
- CPRX $12.18
- Revenue Growth
- LXP 6.63
- CPRX 28.55
- 52 Week Low
- LXP $6.85
- CPRX $19.00
- 52 Week High
- LXP $10.44
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- LXP 53.79
- CPRX 40.47
- Support Level
- LXP $7.87
- CPRX $19.36
- Resistance Level
- LXP $8.29
- CPRX $20.51
- Average True Range (ATR)
- LXP 0.18
- CPRX 0.74
- MACD
- LXP 0.05
- CPRX -0.06
- Stochastic Oscillator
- LXP 91.54
- CPRX 27.22
About LXP LXP Industrial Trust (Maryland REIT)
LXP Industrial Trust is a real estate investment trust principally involved in the ownership of equity and debt investments in single-tenant properties and land throughout the United States. The majority of the revenue is earned through rental revenue.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).